cagrisema semaglutide cagrilintide combination trial is one of the most #potent #weightloss medication developed till date! Cagrisema on an average causes 9% additional weight loss over # 2.4mg/week! Cagrisema is a fixed-dose of semaglutide 2.4mg + # cagrisema is one of the

Glucose Homeostasis: Semaglutide stimulates glucose-dependent insulin secretion from pancreatic -cells while suppressing glucagon release from -cells

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and focusing on nutrient-dense, portion-controlled products.

Main outcome measures Hyperkalemia diagnosis in the inpatient or outpatient setting

However, the existing evidence is limited by small cohort sizes, heterogeneous patient populations, and confounding effects of concurrent therapies, limiting its generalizability

#ad Essentials when on a GLP-1

Food and Drug Administration Adverse Events Reporting System (FAERS) database